Investigating the Influence of Spot Error on Plan Quality: A Comparative Study of Spot-Scanning Arc Therapy (SPArc) and Intensity-Modulated Proton Therapy (IMPT)

Document Type

Conference Proceeding

Publication Date

10-2024

Publication Title

International Journal of Radiation Oncology, Biology, Physics

Abstract

Purpose/Objective(s): To quantitatively assess the impact of spot position errors (PEs) on plan quality in Spot-Scanning Arc Therapy (SPArc) plans compared with Intensity-Modulated Proton Therapy (IMPT). Materials/Methods: Four representative disease sites, including brain, lung, liver, and prostate cancers, were retrospectively selected with. Clinical IMPT plan and dynamic SPArc plan were used as the original plan (PEorig). Two types of errors were generated, including randomized error and systematic error. For each random error scenario, they were further examined across four sub-scenarios (25%, 50%, 75%, and 100% of spots affected) at 1 mm and 2 mm deviations. The randomized errors used two categories with and without Gaussian distribution (PEran-GS, PEran-UN). Systematic errors were simulated by uniformly adjusting all spot positions by 2 mm in varying directions. The Gamma-index Passing Ratio (GPR) was utilized to evaluate dose perturbations relative to nominal plans. Results: For PEran-GS in 1mm scenario, both SPArc and IMPT are comparable with a GPR exceeding 95%. However, for PEran-GS in 2mm scenario, SPArc could provide better GPR. As PEran-UN of 2mm, SPArc plans have a much better GPR compared to IMPT plans: SPArc’s GPR is 99.40§0.74%, 93.66§4.75% and 61.53§10.30% for 3mm/3%, 2mm/2% and 1mm/1% criteria compared to IMPT with 98.18§2.11%, 86.12§5.58% and 39.74§ 7.71%. Besides, SPArc has shown its advantage in dosimetric sparing and robustness in the Organ-at-risks. In the prostate case, SPArc could provide smaller dose difference for the target coverage (D95: 0.46% vs 1.48%) and rectum (mean dose: 0.41% vs 1.33%) compared to IMPT (table1) with similar differences for other OARs. Conclusion: SPArc shows better dosimetric robustness to spot PEs than IMPT, suggesting its enhanced capability for achieving precise dose distribution. This study presents the first simulation results and the methodology that serves as a reference to guide future investigations into quality assurance of SPArc treatment delivery

Volume

120

Issue

2S

First Page

e158

Comments

ASTRO 2024: 66th Annual Meeting American Society for Radiation Oncology, September 29 - October 2, 2024, Washington, DC

DOI

10.1016/j.ijrobp.2024.07.2140

Link to Full Text

Share

COinS